Gilead Sciences (GILD) : Shikiar Asset Management Inc scooped up 20,650 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 20, 2016. The investment management firm now holds a total of 92,385 shares of Gilead Sciences which is valued at $7,995,922.Gilead Sciences makes up approximately 3.41% of Shikiar Asset Management Inc’s portfolio.
Other Hedge Funds, Including , Quantres Asset Management Ltd sold out all of its stake in GILD during the most recent quarter. The investment firm sold 11,300 shares of GILD which is valued $978,015.Nordea Investment Management Ab reduced its stake in GILD by selling 63,962 shares or 2.64% in the most recent quarter. The Hedge Fund company now holds 2,356,349 shares of GILD which is valued at $204,201,204. Gilead Sciences makes up approx 0.58% of Nordea Investment Management Ab’s portfolio.Lgt Capital Partners Ltd. boosted its stake in GILD in the latest quarter, The investment management firm added 31,470 additional shares and now holds a total of 158,180 shares of Gilead Sciences which is valued at $13,563,935. Gilead Sciences makes up approx 2.30% of Lgt Capital Partners Ltd.’s portfolio.Dnb Asset Management As reduced its stake in GILD by selling 37,000 shares or 16.0% in the most recent quarter. The Hedge Fund company now holds 194,282 shares of GILD which is valued at $16,815,107. Gilead Sciences makes up approx 0.35% of Dnb Asset Management As’s portfolio.Osborn Rohs Williams Donohoe Ltd reduced its stake in GILD by selling 608 shares or 1.19% in the most recent quarter. The Hedge Fund company now holds 50,460 shares of GILD which is valued at $4,367,313. Gilead Sciences makes up approx 0.84% of Osborn Rohs Williams Donohoe Ltd’s portfolio.
Gilead Sciences opened for trading at $85.46 and hit $87.12 on the upside on Wednesday, eventually ending the session at $86.66, with a gain of 1.43% or 1.22 points. The heightened volatility saw the trading volume jump to 90,55,877 shares. Company has a market cap of $115,416 M.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.